Drug Controller General of India approves Saroglitazar Mg

Zydus Cadila has received the approval from the Drug Controller General of India for its Saroglitazar Mg used for the treatment of non-alcoholic fatty liver disease in India.

Non-Alcoholic Fatty Liver Disease is a progressive disease of the liver which starts with the fat accumulation in the liver in patients who do not consume alcohol or take it in insignificant amounts but have the risk factors such as overweight, diabetes, hypertension or abnormal blood lipids. NAFLD could further progress to NASH, cirrhosis and liver failure.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Privacy & Cookies Policy